About Noetik
Noetik is a company based in San Francisco (United States) founded in 2022 by Jacob Rinaldi and Ron Alfa. Noetik has raised $62 million across 3 funding rounds from investors including Khosla Ventures, Polaris Partners and Wittington Ventures. Noetik offers products and services including Precision Immunotherapies and Foundation Models. Noetik operates in a competitive market with competitors including Function Oncology, Meliora Therapeutics, Transition Bio, Alixia and OmniSeq, among others.
- Headquarter San Francisco, United States
- Founders Jacob Rinaldi, Ron Alfa
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Noetik Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$62 M (USD)
in 3 rounds
-
Latest Funding Round
$40 M (USD), Series A
Jul 31, 2024
-
Investors
Khosla Ventures
& 20 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Noetik
Noetik offers a comprehensive portfolio of products and services, including Precision Immunotherapies and Foundation Models.
AI-driven treatments targeting cancer through machine learning models
Models for cell and tissue biology in cancer research applications
People of Noetik
Unlock access to complete
Funding Insights of Noetik
Noetik has successfully raised a total of $62M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Noetik
Noetik has secured backing from 21 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Khosla Ventures, Polaris Partners and Wittington Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused venture capital firm
|
Locked | Locked | Locked | |
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Wittington Ventures is engaged in investing in technology start-ups.
|
Locked | Locked | Locked |
Investor details for Noetik
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Noetik
Investment portfolio details for Noetik
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Noetik
Detailed financials for Noetik
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Noetik Comparisons
Peer comparison for Noetik
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Noetik
Noetik operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Function Oncology, Meliora Therapeutics, Transition Bio, Alixia and OmniSeq, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cancer therapeutics are developed using a CRISPR-enabled platform.
|
|
| Locked | Locked | Locked |
Machine learning-driven platform for oncology drug discovery is offered.
|
|
| Locked | Locked | Locked |
Technology platform for biomolecular condensate analysis is developed.
|
|
| Locked | Locked | Locked |
Cancer drug discovery platform is provided for tumor mutation targeting.
|
|
| Locked | Locked | Locked |
Web-based solutions for genomic testing and sequencing access are provided.
|
Detailed competitors of Noetik
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Noetik
Complete news archive for Noetik
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Noetik
Noetik was founded in 2022.
Noetik is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Ron Alfa is the current CEO of Noetik. They have also founded this company.
Noetik is a funded company, having raised a total of $62M across 3 funding rounds to date.
Noetik was founded in 2022 in San Francisco, United States, within the biotechnology sector. An AI-driven platform is utilized for cancer immunotherapy discovery and development. Advanced machine learning is applied to analyze tumor-immune interactions. Self-supervised learning is integrated with multimodal human data to generate foundation models for cell and tissue biology. Operations focus on therapeutic advancements through these computational approaches.
Noetik's top competitors include Transition Bio, Function Oncology and Meliora Therapeutics.
Noetik offers Precision Immunotherapies and Foundation Models.
Noetik has 21 investors. Key investors include Khosla Ventures, Polaris Partners, Wittington Ventures, Breakout Ventures, and DCVC.